Journal Article10.1007/S10072-020-04998-Y
Update on therapy of chronic immune-mediated neuropathies.
19
TL;DR: A number of immune therapies have been reported to be variably effective in chronic immune-mediated neuropathies including steroids, plasma exchange, and high-dose intravenous (IVIg) or subcutaneous immunoglobulins as discussed by the authors, however, these therapies are not always invariably effective and may be associated with a number of side effects leading to the use of immunosuppressive agents whose efficacy has not been so far confirmed in randomized trials.
read more
Abstract: Chronic immune-mediated neuropathies, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), neuropathies associated with monoclonal gammopathy, and multifocal motor neuropathy (MMN), are a group of disorders deemed to be caused by an immune response against peripheral nerve antigens. Several immune therapies have been reported to be variably effective in these neuropathies including steroids, plasma exchange, and high-dose intravenous (IVIg) or subcutaneous (SCIg) immunoglobulins. These therapies are however far from being invariably effective and may be associated with a number of side effects leading to the use of immunosuppressive agents whose efficacy has not been so far confirmed in randomized trials. More recently, new biological agents, such as rituximab, have proved to be effective in patients with neuropathy associated with IgM monoclonal gammopathy and are currently tested in CIDP.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.
Luis Querol,Cinta Lleixà +1 more
TL;DR: In this paper, a topical review describes immunological progress that may help guide therapeutic strategies in the future in inflammatory demyelinating polyradiculoneuropathy (CIDP) and GBS.
32
Rituximab in chronic immune mediated neuropathies: a systematic review
TL;DR: In this paper , a literature search was performed using Medline, Embase and Cochrane Register for studies between 2000 and 2021 using the search terms “Chronic inflammatory demyelinating polyneuropathy” OR “Multifocal motor neuropathy, OR „Myelin associated glycoprotein” or “Distal acquired demyelin-associated neuropathy.
19
Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions
Adeel S. Zubair,Melissa Rethana,Anthony K Ma,Lindsay S. McAlpine,Ahmad Abulaban,B. Munro,Huned S. Patwa,Richard Nowak,Bhaskar Roy +8 more
TL;DR: Both PLEX and IVIg are safe therapeutic choices in adult patients with autoimmune neuromuscular disorders and other neuro-immunological diseases and can be safely administered in the appropriate clinical setting.
5
Intensive Safety Monitoring of Rituximab (Biosimilar Novex® and the Innovator) in Pediatric Patients With Complex Diseases
Natalia Riva,Manuel Molina,Berta L. Cornaló,María Villalba Salvador,Andrea Savransky,Silvia Tenembaum,MM Katsicas,Marta Lidia Monteverde,Paulo Cáceres Guido,Marc Rousseau,Raquel Staciuk,Agustín González Correas,Pedro Zubizarreta,O. Imventarza,Eduardo Lagomarsino,Eduardo Spitzer,Marcelo A. Tinelli,Paula Schaiquevich +17 more
TL;DR: The present is the largest real-world safety assessment of rituximab in Latin-American children with complex diseases supporting its use based on the overall acceptable safety.
3
Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks
Yusuf A. Rajabally
TL;DR: Current therapeutic approaches for CIDP include immunoglobulin therapy, corticosteroids, plasma exchanges, and immunosuppressive medications. New therapeutic options include efgartigimod, haematopoietic stem cell transplants and complement-inhibitor SAR445088.
3
References
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede,Kirsten Fischer,Raymonde Busch,Anja Engelke,Barbara Eichhorst,Clemens M. Wendtner,Tatiana Chagorova,Javier de la Serna,Marie-Sarah Dilhuydy,Thomas Illmer,Stephen Opat,Carolyn Owen,Olga Samoylova,Karl-Anton Kreuzer,Stephan Stilgenbauer,Hartmut Döhner,Anton W. Langerak,Matthias Ritgen,Michael Kneba,Elina Asikanius,Kathryn Humphrey,Michael Wenger,Michael Hallek +22 more
TL;DR: Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions, and obinutuzumab was superior to rituximab when each was combined with chlorambucil.
1.5K
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Steven P. Treon,Christina K. Tripsas,Kirsten Meid,Diane Warren,Gaurav Varma,Rebecca Green,Kimon V. Argyropoulos,Guang Yang,Yang Cao,Lian Xu,Christopher J. Patterson,Scott J. Rodig,James L. Zehnder,Jon C. Aster,Nancy L. Harris,Sandra Kanan,Irene M. Ghobrial,Jorge J. Castillo,Jacob P. Laubach,Zachary R. Hunter,Zeena Salman,Jianling Li,Mei Cheng,Fong Clow,Thorsten Graef,M. Lia Palomba,Ranjana H. Advani +26 more
TL;DR: Ibrutinib was highly active, associated with durable responses, and safe in pretreated patients with Waldenström's macroglobulinemia, and the effect of MYD88 and CXCR4 mutations on outcomes was investigated.
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society : First Revision
Peter Van den Bergh,R. D. M. Hadden,Pierre Bouche,David R. Cornblath,A. Hahn,Isabel Illa,Carol L. Koski,Jean Marc Léger,Eduardo Nobile-Orazio,John D. Pollard,Claudia Sommer,Pieter A. van Doorn,Ivo N. van Schaik +12 more
TL;DR: This work revised consensus guidelines on the definition, investigation, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy by disease experts using references retrieved from MEDLINE and Cochrane Systematic Reviews published between August 2004 and July 2009.
690
A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.
Alan Pestronk,David R. Cornblath,Amjad A. Ilyas,H. Baba,Richard H. Quarles,John W. Griffin,K. Alderson,Robert N. Adams +7 more
TL;DR: 2 patients with a treatable, immune‐mediated motor polyneuropathy associated with antibodies to defined neural antigens, initially diagnosed as having lower motor neuron forms of amyotrophic lateral sclerosis are reported.
645
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial
Richard A. C. Hughes,Peter D. Donofrio,Vera Bril,Marinos C. Dalakas,Chunqin Deng,Kim Hanna,Hans-Peter Hartung,Norman Latov,Ingemar S. J. Merkies,Pieter A. van Doorn +9 more
TL;DR: This study, the largest reported trial of any CIDP treatment, shows the short-term and long-term efficacy and safety of IGIV-C and supports use of IGiv-C as a therapy for C IDP.
632